<DOC>
	<DOC>NCT02462499</DOC>
	<brief_summary>The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.</brief_summary>
	<brief_title>Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population</brief_title>
	<detailed_description />
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Chronic central serous chorioretinopathy (CSCR) with persistent subretinal fluid on OCT for more than 3 months after initial presentation . Written informed consent Persons with impaired decisionmaking ability. Pregnant women or who are actively trying to conceive. Additional eye disease affecting the macula or posterior retina. Creatinine clearance &lt; 50 ml/min Hyperkalemia &gt; 5 mmol/l Serum creatinine &gt; 2 mg/dl in men or &gt; 1.8 mg/dl in women Treatment with potassium sparing agents or potassium Treatment with any other drugs known to cause interaction with eplerenone Microalbuminuria in patients with type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>